Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Microbial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.
Italian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC)
Novo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.
Calypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypsos US$250m upfront upon closing plus of up to US$175.
Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd.
Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.
Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.